Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (16 chapters)
-
Front Matter
-
Basic Principles
-
Front Matter
-
-
Glycoprotein IIb/IIIa Blockade During Coronary Intervention
-
Front Matter
-
-
Glycoprotein IIb/IIIa Blockade for Acute Ischemic Syndromes
-
Front Matter
-
-
Practical Issues and Future Applications
-
Front Matter
-
About this book
Written by the scientists and physicians who discovered and characterized this important new class of receptors, invented the first IIb/IIIa agents, and conducted the definitive clinical trials, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease offers the most complete and authoritative review of these powerful new therapeutics available today.
Reviews
Editors and Affiliations
-
Experimental Interventional Laboratory, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland Clinic Foundation, Cleveland, USA
A. Michael Lincoff
-
Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, USA
A. Michael Lincoff, Eric J. Topol
-
Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland Clinic Foundation, Cleveland, USA
Eric J. Topol
Bibliographic Information
Book Title: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease
Editors: A. Michael Lincoff, Eric J. Topol
Series Title: Contemporary Cardiology
DOI: https://doi.org/10.1007/978-1-59259-724-6
Publisher: Humana Totowa, NJ
-
eBook Packages: Springer Book Archive
Copyright Information: Springer Science+Business Media New York 1999
eBook ISBN: 978-1-59259-724-6
Series ISSN: 2196-8969
Series E-ISSN: 2196-8977
Edition Number: 1
Number of Pages: XIV, 369
Number of Illustrations: 20 b/w illustrations
Topics: Cardiology
Industry Sectors: Biotechnology, Engineering, Finance, Business & Banking, Health & Hospitals, Pharma